SMAD3 Gene Mutation Analysis
The SMAD3 Gene is located on the long (q) arm of chromosome 15 at position 22.33 and encodes SMAD family member 3 (SMAD3) also known as mothers against decapentaplegic homolog 3. SMAD proteins are signal transducers and transcriptional modulators that mediate multiple signaling pathways. SMAD3 acts as a mediator of signals initiated by transforming growth factor beta (TGF-β). This protein influences many aspects of cellular processes, including cell growth and division, cell movement and apoptosis. Based on its essential role in the TGF beta signaling pathway, somatic mutations of SMAD3 are associated with cancer development. Inherited mutations in the SMAD3 gene cause Loeys-Dietz syndrome type III and familial thoracic aortic aneurysms and dissections (TAAD).
Loeys-Dietz syndrome type III (LDS) is an autosomal dominant disorder of connective tissue that affects blood vessels, bones, and many other parts of the body. Two major clinical features characterize LDS: vascular findings (cerebral, thoracic, and abdominal arterial aneurysms and/or dissections) and skeletal manifestations (pectus excavatum or pectus carinatum, scoliosis, joint laxity, arachnodactyly, talipes equinovarus). Additional variable features include craniofacial abnormalities (ocular hypertelorism, bifid uvula/cleft palate and craniosynostosis) and cutaneous findings (translucent skin, easy bruising and dystrophic scars). Mutations of SMAD3 in LDS typically result in loss of function and are nonsense or frameshift mutations due to small insertions or deletions. Despite a reduction in SMAD3 function, the TGF-β pathway becomes overactive and the increased signaling leads to dysregulated cell proliferation and gene activation.
Familial thoracic aortic aneurysm and dissection (familial TAAD) causes aneurysmal dilatation of the aorta which predisposes to aortic dissection and life threatening bleeding. The SMAD3 gene mutations that cause familial TAAD disturb signal transduction, which can impair cell growth and development. Up to 20% of individuals with TAAD who do not have a known syndrome (e.g., Marfan syndrome, vascular Ehlers-Danlos syndrome, or Loeys-Dietz syndrome) have a family history of TAAD. Approximately 30% of families with heritable thoracic aortic disease (HTAD) who do not have another clinical syndrome have a causative pathogenic variant in one of the known HTAD-related genes: FBN1, TGFBR1, TGFBR2 and SMAD3.
- For evaluation of the clinical diagnosis of Loeys-Dietz syndrome type III and familial thoracic aortic aneurysm and dissection (familial TAAD)
- Risk assessment of asymptomatic family members of a proband with familial thoracic aortic aneurysm and dissection (familial TAAD)
- Carrier screening and predictive testing of at-risk family members
- Prenatal testing for pregnancies at increased risk and preimplantation genetic diagnosis
Positive: Mutation or pathogenic variant in SMAD3 gene. Pathogenic variants may include small intragenic deletions/insertions and missense, nonsense, and splice site variants.
Negative: No mutation or pathogenic variant in SMAD3 gene.
Negative for mutation or pathogenic variant in SMAD3 gene
Whole blood, amniocytes or cultured CVS cells (prenatal samples).
Stability
- Ambient: 3-5 days
- Refrigerated: 7-14 days
- Frozen: Unacceptable
- Circ Res. 2011;109: 680-6. [PMID: 21778426]
- Am J Med Genet A. 2013;161A: 1028-35. [PMID: 23554019]
- Hum Mutat. 2018;39: 621-634. [PMID: 29392890]
- Eur J Hum Genet. 2003 Sep;11(9):714-7. [PMID: 12939660]
- Circ Res. 2011 Sep 2;109(6):680-6. [PMID: 21778426]
- Biomed Res Int. 2015;2015:968135. [PMID: 26221609]
- Genetics Home Reference. Available at: https://ghr.nlm.nih.gov/gene/SMAD3#sourcesforpage